AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22873013 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 1426
Study 19254337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Low Back Pain (CLBP)
Number of subjects: 288
Study 17302651 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured telephone geriatric assessment by a physician assistant, individualized referrals and recommendations, selected referral to outpatient geriatric assessment, and ongoing telephone case management.
Number of subjects: 792
Study 17302651 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 792
Study 15220164 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL 30 ml kg(-1)
Number of subjects: 141
Study 11588120 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 100 nmol min(‐1)
Number of subjects: 20
Study 11588120 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 300 nmol min(‐1)
Number of subjects: 20
Study 11588120 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 1000 nmol min(‐1)
Number of subjects: 20
Study 11588120 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 3000 nmol min(‐1)
Number of subjects: 20
Study 11588120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9564607 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 37
Study 7817627 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss HIV Cohort Study (SHCS)
Number of subjects: 6253
Study 3354545 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training in procedures to reduce transmission of infectious diarrhea
Number of subjects: 21
Study 3354545 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 21
Study 3354545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no staff training)
Number of subjects: 21
Study 3354545 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly family-based surveys
Number of subjects: 21
Study 3354545 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time staff training without subsequent monitoring
Number of subjects: 21
Study 31453902 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterograde technique
Number of subjects: 44
Study 31453902 — intervention group
Group type: COMPARATOR
Intervention: Retrograde technique
Number of subjects: 44
Study 31504139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine (T-DM1) at 3.6 mg/kg intravenously every 3 weeks until toxicity or disease progression
Number of subjects: 36
Study 31504139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine (T-DM1)
Number of subjects: 36
Study 28454060 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannula oxygen (HHFNC O2)
Number of subjects: 51
Study 28454060 — intervention group
Group type: COMPARATOR
Intervention: Conventional O2 therapy (control)
Number of subjects: 51
Study 26409117 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR, 1800 mg)
Number of subjects: 546
Study 23998674 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased functional connectivity between the dorsomedial prefrontal cortex (DMPFC) and the right posterior superior temporal sulcus (pSTS) during social emotion processing compared to basic emotion processing.
Number of subjects: 0
Study 23998674 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased functional connectivity between the DMPFC and the right TPJ during social emotion processing, associated with increasing oestradiol concentrations.
Number of subjects: 0
Study 23998674 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced functional connectivity between the DMPFC and the left anterior temporal cortex (ATC) during social emotion processing, associated with more advanced puberty stage.
Number of subjects: 0
Study 21572124 — intervention group
Group type: EXPERIMENTAL
Intervention: sialyl-TN (STn) keyhole limpet hemocyanin (KLH) vaccine
Number of subjects: 1028
Study 21572124 — intervention group
Group type: COMPARATOR
Intervention: 100 μg KLH plus adjuvant (control group)
Number of subjects: 1028
Study 19173846 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based hypertension self-management program
Number of subjects: 373
Study 19173846 — intervention group
Group type: COMPARATOR
Intervention: Routine hypertension management services (Control)
Number of subjects: 373
Study 16508317 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI + eradication (group 2)
Number of subjects: 61
Study 16508317 — intervention group
Group type: COMPARATOR
Intervention: PPI‐only (group 1)
Number of subjects: 61
Study 12699477 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary
Number of subjects: 35
Study 12699477 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 35
Study 10974959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management (case-loads 10-15)
Number of subjects: 708
Study 10974959 — intervention group
Group type: COMPARATOR
Intervention: Standard case management (case-loads 30-35)
Number of subjects: 708
Study 10974959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 708
Study 10974959 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 708
Study 9006235 — intervention group
Group type: EXPERIMENTAL
Intervention: THR education booklet received in the mail 4-6 weeks before surgery
Number of subjects: 0
Study 9006235 — intervention group
Group type: COMPARATOR
Intervention: No Booklet (control group)
Number of subjects: 0
Study 1616214 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin, 400 mg, twice daily for 5 days
Number of subjects: 511
Study 1616214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 6232402 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-micrograms dose of HBsAg vaccine administered at 0, 1, and 6 months
Number of subjects: 37
Study 6232402 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-micrograms dose of HBsAg vaccine
Number of subjects: 37
Study 3723285 — intervention group
Group type: EXPERIMENTAL
Intervention: Film 'Touch' (Illusion Theater Co. & Media Ventures, Inc., 1984)
Number of subjects: 67
Study 3723285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no film)
Number of subjects: 67
Study 29455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LASER (904 nm, 60 mW, 250 Hz, 3.6 J per diode, total dose of 129.6 J)
Number of subjects: 18
Study 29455305 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LASER (904 nm)
Number of subjects: 18
Study 29455305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27578220 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive metformin therapy (in addition to insulin)
Number of subjects: 84
Study 27578220 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (control group)
Number of subjects: 84
Study 27578220 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive metformin therapy
Number of subjects: 84
Study 23824087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program
Number of subjects: 937
Study 23824087 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 937
Study 23939415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear mixed effects modeling of diurnal systolic blood pressure (SBP)
Number of subjects: 196
Study 19484712 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet peer support condition
Number of subjects: 78
Study 19484712 — intervention group
Group type: COMPARATOR
Intervention: Internet-based educational control condition
Number of subjects: 78
Study 18257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe rectocele
Number of subjects: 11096
Study 18257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe prolapse
Number of subjects: 11096
Study 16637746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful faces
Number of subjects: 0
Study 16637746 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned neutral faces
Number of subjects: 0
Study 16637746 — intervention group
Group type: COMPARATOR
Intervention: Neutral faces
Number of subjects: 0
Study 12909597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest for 6 days
Number of subjects: 8
Study 12909597 — intervention group
Group type: COMPARATOR
Intervention: Non-bed rest period
Number of subjects: 8
Study 10790249 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment music tape (TT)
Number of subjects: 0
Study 10790249 — intervention group
Group type: COMPARATOR
Intervention: Familiar music tape (FT)
Number of subjects: 0
Study 10790249 — intervention group
Group type: COMPARATOR
Intervention: No audiotape (NT)
Number of subjects: 0
Study 8864317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg single oral dose after stopping SASP for 2 weeks
Number of subjects: 15
Study 8864317 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg weekly + 2000 mg SASP daily
Number of subjects: 15
Study 8864317 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measurements (Ritchie articular index, number of swollen joints, ESR, disease activity score)
Number of subjects: 15
Study 1633285 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill movement with optical flow pattern (0.25 Hz)
Number of subjects: 0
Study 6094442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and metronidazole
Number of subjects: 0
Study 6094442 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and tobramycin
Number of subjects: 0
Study 30274758 — intervention group
Group type: EXPERIMENTAL
Intervention: FA training only
Number of subjects: 317
Study 30274758 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + HC training
Number of subjects: 317
Study 30274758 — intervention group
Group type: COMPARATOR
Intervention: No prior training
Number of subjects: 317
Study 30274758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior FA + HC training
Number of subjects: 317
Study 30243296 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloader One® Knee Brace
Number of subjects: 149
Study 30243296 — intervention group
Group type: COMPARATOR
Intervention: Control placebo group (look-alike brace with active strips removed)
Number of subjects: 149
Study 26600556 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised training
Number of subjects: 55
Study 26600556 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 55
Study 24853922 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing
Number of subjects: 38
Study 22575499 — intervention group
Group type: EXPERIMENTAL
Intervention: PALs intervention
Number of subjects: 100
Study 20087340 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs (888 drugs connected to side effects)
Number of subjects: 888
Study 20087340 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration (199 drugs)
Number of subjects: 888
Study 18593998 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-275183 administered under fasting conditions (A)
Number of subjects: 31
Study 18593998 — intervention group
Group type: COMPARATOR
Intervention: BMS-275183 administered after a low-fat meal (B)
Number of subjects: 31
Study 18593998 — intervention group
Group type: COMPARATOR
Intervention: BMS-275183 administered after a high-fat meal (C)
Number of subjects: 31
Study 18593998 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-275183 administered with BSA-normalized dosing (D)
Number of subjects: 31
Study 18593998 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-275183 overall
Number of subjects: 31
Study 15653291 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-cueing conditions (informative pre-cues)
Number of subjects: 0
Study 15653291 — intervention group
Group type: COMPARATOR
Intervention: No task-cueing conditions (uninformative pre-cues)
Number of subjects: 0
Study 12521503 — intervention group
Group type: EXPERIMENTAL
Intervention: Propess (slow release prostaglandin pessary)
Number of subjects: 95
Study 12521503 — intervention group
Group type: COMPARATOR
Intervention: Prostin gel (instant release prostaglandin gel)
Number of subjects: 95
Study 12521503 — intervention group
Group type: EXPERIMENTAL
Intervention: Propess
Number of subjects: 95
Study 9673744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised terbutaline (cumulative dose 10 mg)
Number of subjects: 18
Study 9673744 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 18
Study 8022954 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Number of subjects: 204
Study 2562913 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal alone
Number of subjects: 200
Study 2562913 — intervention group
Group type: COMPARATOR
Intervention: Syrup of ipecac and activated charcoal
Number of subjects: 200
Study 792737 — intervention group
Group type: EXPERIMENTAL
Intervention: parsalmide
Number of subjects: 40
Study 792737 — intervention group
Group type: COMPARATOR
Intervention: phenybutazone
Number of subjects: 40
Study 30861998 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 20
Study 30861998 — intervention group
Group type: COMPARATOR
Intervention: Usual care + conventional physical therapy
Number of subjects: 20
Study 30106636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab and an aromatase inhibitor (AI)
Number of subjects: 129
Study 30106636 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab and an AI
Number of subjects: 129
Study 30106636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 129
Study 30106636 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 129
Study 27401244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib plus mFOLFOX6 (1.5 mg orally once daily for 21 days)
Number of subjects: 0
Study 27401244 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus mFOLFOX6 (5 mg/kg intravenously every 2 weeks)
Number of subjects: 0
Study 27401244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tivozanib plus mFOLFOX6
Number of subjects: 0
Study 23909813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (10 g)
Number of subjects: 41
Study 23909813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (10 g)
Number of subjects: 41
Study 23909813 — intervention group
Group type: COMPARATOR
Intervention: Glucose (10 g)
Number of subjects: 41
Study 23909813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both polyols (sorbitol and mannitol)
Number of subjects: 41
Study 21252373 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with LD using assistive technology and web courses
Number of subjects: 964
Study 21252373 — intervention group
Group type: EXPERIMENTAL
Intervention: Students with LD
Number of subjects: 964
Study 21252373 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (students without LD)
Number of subjects: 964
Study 19579757 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal PRBC transfusion criteria (n=17)
Number of subjects: 36
Study 19579757 — intervention group
Group type: COMPARATOR
Intervention: Restrictive PRBC transfusion criteria (n=19)
Number of subjects: 36
Study 19579757 — intervention group
Group type: EXPERIMENTAL
Intervention: Total transfused blood volume greater than 30 mL over 30 days
Number of subjects: 36
Study 17210036 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine A(2A) receptor agonist/adenosine A(3) receptor antagonist (50 micro g), administered twice daily for 7 days
Number of subjects: 48
Study 17210036 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fluticasone proprionate nasal spray (FPANS), administered twice daily for 7 days
Number of subjects: 48
Study 17210036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15177710 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 12
Study 15177710 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12
Study 11585150 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with air
Number of subjects: 20
Study 11585150 — intervention group
Group type: COMPARATOR
Intervention: Training with oxygen
Number of subjects: 20
Study 9413755 — intervention group
Group type: EXPERIMENTAL
Intervention: No antibiotic prophylaxis (sterile urine group)
Number of subjects: 340
Study 9413755 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (urinary tract infection group)
Number of subjects: 340
Study 8004733 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg)
Number of subjects: 60
Study 8004733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 60
Study 8004733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 3316565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 16
Study 3316565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3316565 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime and Placebo
Number of subjects: 16
Study 31489650 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg PTX in 3 divided doses plus 25 mg captopril 3 times a day
Number of subjects: 62
Study 31489650 — intervention group
Group type: COMPARATOR
Intervention: 75 mg captopril in 3 divided doses
Number of subjects: 62
Study 30359047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) system for daily monitoring of illicit opioid use
Number of subjects: 24
Study 30359047 — intervention group
Group type: COMPARATOR
Intervention: Timeline Follow-Back (TLFB) interviews
Number of subjects: 24
Study 28723843 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate (CHO) manipulation (414 ± 2.4 g)
Number of subjects: 26
Study 28723843 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate (CHO) manipulation (79.5 ± 1.0 g)
Number of subjects: 26
Study 28723843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (High and Low CHO)
Number of subjects: 26
Study 25355640 — intervention group
Group type: EXPERIMENTAL
Intervention: T/T genotype of XRCC2 -41657C/T polymorphism
Number of subjects: 1008
Study 25355640 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of XRCC2 polymorphism
Number of subjects: 1008
Study 25355640 — intervention group
Group type: COMPARATOR
Intervention: XRCC2 -41657C/T genotypes in subgroups assigned to histological grades
Number of subjects: 1008
Study 23283805 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 610
Study 23283805 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 610
Study 20492049 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to specially selected, relaxing music at home for at least 30 minutes a day over two weeks
Number of subjects: 77
Study 20492049 — intervention group
Group type: COMPARATOR
Intervention: Regular postpartum care only
Number of subjects: 77
Study 19019818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alive! intervention group
Number of subjects: 787
Study 17030754 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI (quintiles of BMI at baseline)
Number of subjects: 2223
Study 17030754 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI at baseline
Number of subjects: 2223
Study 17030754 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in BMI
Number of subjects: 2223
Study 12879828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritized review criteria for asthma and angina
Number of subjects: 81
Study 12879828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritized review criteria plus feedback for asthma and angina
Number of subjects: 81
Study 12879828 — intervention group
Group type: COMPARATOR
Intervention: Full guidelines for asthma and angina
Number of subjects: 81
Study 11291296 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 50
Study 8973991 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein food
Number of subjects: 12
Study 8973991 — intervention group
Group type: COMPARATOR
Intervention: Control (no high-protein food)
Number of subjects: 12
Study 8198418 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms)
Number of subjects: 10
Study 8198418 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (72 micrograms)
Number of subjects: 10
Study 8198418 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four puffs)
Number of subjects: 10
Study 2443727 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck resection
Number of subjects: 30
Study 2443727 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate
Number of subjects: 30
Study 29239242 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole-loaded solid lipid nanoparticles (FLZ-SLNs) topical gel
Number of subjects: 30
Study 29239242 — intervention group
Group type: COMPARATOR
Intervention: Candistan® 1% cream (control)
Number of subjects: 30
Study 27548351 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 325
Study 24259750 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrocnemius stretching in pronation
Number of subjects: 27
Study 24259750 — intervention group
Group type: COMPARATOR
Intervention: Gastrocnemius stretching in supination
Number of subjects: 27
Study 22784254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI) treatment in Graves' disease patients
Number of subjects: 28
Study 22784254 — intervention group
Group type: COMPARATOR
Intervention: Propylthiouracil (PTU) treatment
Number of subjects: 28
Study 22784254 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI treatment
Number of subjects: 28
Study 20653820 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR combined with DBBM hydrated in saline (DBBM-)
Number of subjects: 45
Study 20653820 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR combined with DBBM hydrated in gentamicin sulphate (DBBM+)
Number of subjects: 45
Study 20653820 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR alone
Number of subjects: 45
Study 20653820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no grafting)
Number of subjects: 45